Blog & Resources Camargo Blog October 4th, 2011

Stability Changes Coming to ANDAs

This post comes from D.C. where I am attending the GPhA Fall Technical Conference. We just completed a presentation by FDA’s Glen Smith. He detailed the proposed new stability requirements for ANDA drug products. It is essentially the adoption of ICH Q1A. For readers of this blog, we know that 505(b(2) NDA’s must have 12 months real-time and 6 months accelerated stability on 3 batches at the time of filing. Until now, ANDA’s had to have just 3 months of accelerated stability data at filing to get 2 years of shelf life – confirmed later by RT data.

The new proposal is to essentially have ANDA’s have the same filing requirements as NDA’s. The only significant difference I see is that the ANDA filing would be based on 2 ‘pilot’ and one ‘smaller’ batch. OGD’s Mr. Smith would/could not answer the question as to what the ‘pilot’ size is.

The proposal is nearing the post of a draft guidance for comments after which there will be an implementation period of unannounced duration.

What does this mean for 505(b)(2) companies? It means that an ANDA will take 9 months longer before filing and cost more to develop.

Additional stability requirements, generic user fees and the increased documentation required by QbD will continue to put pressure on the smaller generic companies.

Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.

Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.

9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
2505 Meridian Parkway
Suite 150
Durham NC, 27713
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights